Evidence map›Paper›PMID 36225583›Full record

ArticleFrontiers in pharmacology2022

Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors.

Weize Huang, Felix Stader, Phyllis Chan, Colby S Shemesh, Yuan Chen, Katherine L Gill, Hannah M Jones, Linzhong Li, Gianluca Rossato, Benjamin Wu and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Weize HuangGenentech Inc, South San Francisco, CA, United States.
Felix StaderCertara UK Limited, Sheffield, United Kingdom.
Phyllis ChanGenentech Inc, South San Francisco, CA, United States.
Colby S ShemeshGenentech Inc, South San Francisco, CA, United States.
Yuan ChenGenentech Inc, South San Francisco, CA, United States.
Katherine L GillCertara UK Limited, Sheffield, United Kingdom.
Hannah M JonesCertara UK Limited, Sheffield, United Kingdom.
Linzhong LiCertara UK Limited, Sheffield, United Kingdom.
Gianluca RossatoF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Benjamin WuGenentech Inc, South San Francisco, CA, United States.
Jin Y JinGenentech Inc, South San Francisco, CA, United States.
Pascal ChanuGenentech Inc, South San Francisco, CA, United States.
Roche (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

alveolar soft part sarcomaatezolizumabclinical pharmacologypediatric extrapolationpediatric oncologyphysiologically-based pharmacokinetic (PBPK) modelingquantitative pharmacologysolid tumor

Identifiers

PMID36225583
PMCPMC9548535
OpenAlexW4297236352

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.